High-intensity focused ultrasound shows efficacy as salvage therapy post-external beam radiation therapy

Salvage high-intensity focused ultrasound (HIFU) appears to be an effective treatment option for locally recurrent prostate cancer after primary external beam radiation therapy (EBRT), data from analyses of 6-year oncologic outcomes show.

Related Videos

Related Content

Advertisement

February 5th 2025

Genomic subtyping may help predict clinical outcomes in bladder cancer

Hannah Clarke

In total, 28% of patients with luminal tumors and 41% of patients with non-luminal tumors experienced upstaging to non-organ confined disease.

January 29th 2025

Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

February 3rd 2025

AI and wearables: The new age of smart sex

Dayna R. Smerina Amy M. Pearlman, MD

"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors.

Related Content

Advertisement

February 5th 2025

Genomic subtyping may help predict clinical outcomes in bladder cancer

Hannah Clarke

In total, 28% of patients with luminal tumors and 41% of patients with non-luminal tumors experienced upstaging to non-organ confined disease.

January 29th 2025

Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

February 3rd 2025

AI and wearables: The new age of smart sex

Dayna R. Smerina Amy M. Pearlman, MD

"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors.